Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4
Alimentary Pharmacology and Therapeutics Jan 19, 2018
El-Khayat H, et al. - In this study, the efficacy and safety of daclatasvir and sofosbuvir combination therapy (SOF/DCV) were investigated for the treatment of patients with hepatitis C-related liver cirrhosis genotype 4. In treating patients with hepatitis C-related liver cirrhosis genotype 4, the SOF/DCV combination therapy was found to be effective and safe.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
